Kenneth Carl Anderson C4 Therapeutics, Inc. (CCCC) insider trading activity

CCCC Quotes by TradingView

Kenneth Carl Anderson is Director of C4 Therapeutics, Inc.. Currently has a direct ownership of 116,694 shares of CCCC, which is worth approximately $442,270. The most recent transaction as insider was on Oct 01, 2024, when has been sold 2,023 shares (Common Stock) at a price of $5.56 per share, resulting in proceeds of $11,247. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 117K
1.76% 3M change
6.83% 12M change
Total Value Held $442,270

Kenneth Carl Anderson Transaction History

Date Transaction Value Shares Traded Shares Held Form
Oct 01 2024
BUY
Grant, award, or other acquisition
$11,247 $5.56 p/Share
2,023 Added 1.7%
116,694 Common Stock
Jul 01 2024
BUY
Grant, award, or other acquisition
$11,252 $4.85 p/Share
2,320 Added 1.98%
114,671 Common Stock
Apr 01 2024
BUY
Grant, award, or other acquisition
$11,250 $8.1 p/Share
1,389 Added 1.22%
112,351 Common Stock
Jan 02 2024
BUY
Grant, award, or other acquisition
$11,247 $6.52 p/Share
1,725 Added 1.53%
110,962 Common Stock
Oct 02 2023
BUY
Grant, award, or other acquisition
$11,248 $1.7 p/Share
6,617 Added 5.71%
109,237 Common Stock
Jul 03 2023
BUY
Grant, award, or other acquisition
$11,252 $2.83 p/Share
3,976 Added 3.73%
102,620 Common Stock
Apr 03 2023
BUY
Grant, award, or other acquisition
$11,251 $3.2 p/Share
3,516 Added 3.44%
98,644 Common Stock
Jan 06 2023
BUY
Exercise of conversion of derivative security
$2,527 $3.55 p/Share
712 Added 0.74%
95,128 Common Stock
Jan 03 2023
BUY
Grant, award, or other acquisition
$10,003 $6.38 p/Share
1,568 Added 1.63%
94,416 Common Stock
Oct 03 2022
BUY
Exercise of conversion of derivative security
$2,528 $3.55 p/Share
712 Added 0.77%
91,698 Common Stock
Oct 03 2022
BUY
Grant, award, or other acquisition
$9,993 $8.69 p/Share
1,150 Added 1.22%
92,848 Common Stock
Jul 15 2022
BUY
Exercise of conversion of derivative security
$5,055 $3.55 p/Share
1,424 Added 1.54%
90,986 Common Stock
Jul 01 2022
BUY
Grant, award, or other acquisition
$10,005 $8.03 p/Share
1,246 Added 1.37%
89,562 Common Stock
Apr 04 2022
BUY
Grant, award, or other acquisition
$9,023 $26.46 p/Share
341 Added 0.38%
88,316 Common Stock
Jan 26 2022
BUY
Exercise of conversion of derivative security
$7,586 $3.55 p/Share
2,137 Added 2.37%
87,975 Common Stock
Jan 04 2022
BUY
Grant, award, or other acquisition
$8,779 $31.58 p/Share
278 Added 0.32%
85,838 Common Stock
Oct 04 2021
BUY
Grant, award, or other acquisition
$8,728 $44.99 p/Share
194 Added 0.23%
85,560 Common Stock
Jul 02 2021
BUY
Grant, award, or other acquisition
$8,738 $39.72 p/Share
220 Added 0.26%
85,366 Common Stock
Apr 14 2021
BUY
Exercise of conversion of derivative security
$2,524 $3.55 p/Share
711 Added 0.83%
85,146 Common Stock
Apr 13 2021
BUY
Bona fide gift
-
2,278 Added 2.63%
84,435 Common Stock
Apr 05 2021
BUY
Grant, award, or other acquisition
$8,740 $37.51 p/Share
233 Added 0.28%
82,157 Common Stock
Jan 22 2021
BUY
Exercise of conversion of derivative security
$4,752 $3.07 p/Share
1,548 Added 1.85%
81,924 Common Stock
Oct 06 2020
BUY
Conversion of derivative security
-
18,040 Added 18.33%
80,376 Common Stock
KCA

Kenneth Carl Anderson

Director
Watertown, MA

Track Institutional and Insider Activities on CCCC

Follow C4 Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CCCC shares.

Notify only if

Insider Trading

Get notified when an C4 Therapeutics, Inc. insider buys or sells CCCC shares.

Notify only if

News

Receive news related to C4 Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on CCCC